ArticleMolecular microbiology2026
A Single-Nucleotide Substitution Generates a de Novo Promoter That Activates a Latent Metabolic Bypass in Escherichia coli.
Article in Molecular microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The Escherichia coli fabH gene encodes the 3-ketoacyl-ACP synthase III that initiates fatty acid synthesis. Deletion of the fabH gene results in severely limited fatty acid synthesis and tiny cells that are unusually sensitive to antibiotics. Genetic investigations identified the yiiD gene, now called madA, that encodes a malonyl-ACP decarboxylase that suppresses the ∆fabH phenotype, but only when madA is multicopy. We selected vancomycin-resistant suppressor derivatives of a ∆fabH strain. Although such chromosomal mutations were generally rare and weak, suppressor strain s1 (a single C-T transition) restored both wild-type growth, high-level vancomycin resistance, and wild-type fatty acid synthesis by creation of a new promoter within the coding sequence of a gene upstream of madA. This provides a caveat to the extensive effort to develop FabH inhibitors as antibacterial drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.